245 results about "Influenza C Virus" patented technology

The invention relates to an influenza virus subjected to site-directed mutation or an influenza virus with simultaneous mutation of multiple sites. The influenza virus can be derived from human and other animals. The invention further relates to a method of the site-directed mutated influenza virus. The method includes introducing UAG into an influenza virus genome according to a reverse inheritance technology and introducing unnatural amino acid into an influenza virus gene in a site-directed way according to a gene codon extension technology. The invention further relates to application of the site-directed mutated influenza virus or the influenza virus with multiple mutation site combinations, such as serving as attenuated live vaccines and copying controllable safe influenza virus models.

The subject invention provides materials and methods for treating various health conditions, including the prevention and / or treatment of a viral infection. In a preferred embodiment, a cysteamine compound is administered to a subject to treat an influenza virus infection. More preferably, a cysteamine compound is administered to a subject to treat influenza A, influenza B, influenza C virus infections, including avian influenza virus subtypes (such as H5N1 avian influenza virus).

The invention relates to the field of influenza vaccine production. Influenza vaccines have been produced in embryonated hens' eggs for over 50 years, but recently there have been considerable efforts to develop cell culture systems for vaccine production. The invention provides a nucleic acid comprising an influenza gene segment and a bacteriophage polymerase promotor or a complementary strand of said nucleic acid, and a cell comprising such a nucleic acid capable of producing desired influenza virus. Furthermore, the invention provides a composition comprising a cell or material derived from a cell according to the invention and a virus or material derived from a viral particle according to the invention.

The invention provides peptide epitopes for use in the prevention and / or treatment of influenza or for the development of such treatment or vaccine against influenza. The invention also relates to a method for evaluating the potential of a chemical entity, such as an antibody, to bind to a peptide epitope derived from the divalent sialoside binding site of hemagglutinin protein of influenza virus, and to conjugates containing one or more such peptide epitopes. The peptide epitopes of the invention are cyclic peptides comprising a 7-mer peptide derived from H1, H3 or H5 hemagglutinin of influenza virus. The 7-mer peptide has a sequence corresponding to the loop sequence at positions 220-226 of X31-hemagglutinin.

Described herein are chimeric influenza virus gene segments and nucleic acid sequences encoding such chimeric influenza virus gene segments. A chimeric influenza virus gene segment described herein comprises packaging signals found in the non-coding and coding regions of one type of influenza virus gene segment and an open reading frame of a different type of influenza virus gene segment or fragment thereof. Also described herein are recombinant influenza viruses comprising two or more chimeric influenza virus gene segments and the use of such viruses in the prevention and / or treatment of influenza virus disease.

This patent application discloses siRNA sequences against the constant region of the influenza virus nucleoprotein gene comprising:Sense strand:5′ UGAAGGAUCUUAUUUCUUCdTdT 3′(SEQ ID NO: 1)Anti sense strand:3′ dTdTACUUCCUAGAAUAAAGAAG 5′(SEQ ID NO: 2)Sense strand:5′ UGAAGGAUCUUAUUUCUUCGGdTdT 3′(SEQ ID NO: 3)Anti sense strand:3′ dTdTACUUCCUAGAAUAAAGAAGCC 5′(SEQ ID NO: 4)Sense strand:5′ GGAUCUUAUUUCUUCGGAGACdTdT 3′(SEQ ID NO: 5)Anti sense strand:3′ dTdTCCUAGAAUAAAGAAGCCUCUG 5′(SEQ ID NO: 6)said sequences being inhibitory against influenza virus in animals including humans. The invention further includes one or more of said siRNA sequences in the form of an aqueous suspension suitable for nasal inhalation. Still further, the invention includes one or more of said siRNA sequences in the form of a plasmid expressing intracellularly in animals including humans. In another aspect, the invention includes one or more of said siRNA sequences in the form of an AAV vector adapted to express intercellularly and establish a permanent inhibitory effect against influenza virus by integrating to the cellular chromosome of animals including humans. The invention also includes the administration to an animal including humans, in a therapeutically effective amount, at least one of said siRNA sequences.

Described in this application are attenuated strains of avian influenza virus containing temperature sensitive mutations in addition to a genetic tag in the PB1 gene. The attenuated viruses are useful as avian and mammalian vaccine for protective immunity against homologous and heterologous lethal challenges with influenza virus. A genetically modified avian influenza virus backbone is described which can be used as a master donor strain for the generation of live attenuated vaccines for epidemic and pandemic influenza.

A dry powder formulation for delivery to a mammal by inhalation, the formulation comprising particles comprising a lipid, a carrier, and one or more double-stranded siRNA molecules or dicer-active precursors targeted to influenza virus A method for treating or preventing influenza in a mammal comprising administering a therapeutically-effective amount of a dry powder formulation.